Assembly Biosciences Advances HSV-2 Treatment Study with ABI-1179

Assembly Biosciences Inc ((ASMB)) announced an update on their ongoing clinical study.

Study Overview: Assembly Biosciences Inc. is conducting a Phase 1a/1b study titled A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABI-1179, a potential treatment for recurrent genital herpes caused by HSV-2, highlighting its significance in addressing this common viral infection.

Intervention/Treatment: The study tests ABI-1179, an experimental drug administered as a tablet. It is designed to assess the effects of single ascending doses (SAD) in healthy participants and multiple ascending doses (MAD) in HSV-2 seropositive individuals, with a focus on safety and pharmacokinetics.

Study Design: This interventional study employs a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. The primary purpose is treatment-focused, aiming to establish the safety and efficacy of ABI-1179.

Study Timeline: The study began on November 8, 2024, with the last update on August 26, 2025. These dates are crucial as they mark the study’s progression and the latest information available, indicating ongoing recruitment and data collection.

Market Implications: The progress of this study could significantly impact Assembly Biosciences’ stock performance and investor sentiment, as successful results may lead to a new treatment option for HSV-2, a competitive market. Investors should watch for updates, as positive outcomes could enhance the company’s market position.

The study is ongoing, with further details available on the ClinicalTrials portal.